Clinical Trials Logo

Clinical Trial Summary

This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.


Clinical Trial Description

This is a two part, open-label, randomized, 4-period, 4-treatment (per study part) crossover study in healthy subjects (males and females of non-childbearing potential), performed at a single study center, conducted to establish the bioequivalence of 2 strengths of dapagliflozin/metformin XR tablets manufactured at two different plants. ;


Study Design


Related Conditions & MeSH terms

  • Healthy Subjects in Fasted and Fed State

NCT number NCT03216278
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date September 26, 2017
Completion date May 22, 2018